ARS Pharmaceuticals (SPRY) News Today

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is facing continued legal and reputational pressure from a wave of investor-alert announcements regarding a securities class action. The litigation overhang is the primary news-driven factor affecting the stock, although the shares increased during the referenced trading session despite remaining near their one-year low and well below the one-year high.

• Negative Sentiment: Multiple law firms announced that a federal securities class action has been filed against ARS Pharmaceuticals and certain executives, including Chief Commercial Officer Eric Karas. The lawsuit alleges investors were misled about the timing of expanded CVS Caremark coverage for neffy, ARS’s epinephrine nasal spray. The allegations have not been proven. SueWallSt investor alert
• Negative Sentiment: The complaints relate to a reported single-session decline of 23.9% in SPRY shares on June 24, 2026, after investors allegedly learned that expanded CVS Caremark coverage for neffy would not occur as previously expected. This raises potential financial, legal and disclosure risks for the company. Levi & Korsinsky shareholder alert
• Negative Sentiment: Investors who purchased ARS securities between March 9 and June 24, 2026, are being encouraged to seek lead-plaintiff status by October 5, 2026. The repeated notices from Kaplan Fox, Pomerantz, Rosen, Faruqi & Faruqi and other firms increase visibility around the dispute, potentially weighing on investor sentiment and adding uncertainty. Kaplan Fox class-action notice